Spring Bank Pharmaceuticals Inc
Spring Bank Pharmaceuticals — Merger or Acquisition (July 2020)
20 slides from Spring Bank Pharmaceuticals's merger presentation, Jul 30, 2020
Slide 1: Spring Bank Pharmaceuticals and F-star Therapeutics Combination
30th July 2020 Spring Bank Pharmaceuticals and F-star Therapeutics Combination Redirecting T Cells . Overcoming Cancer . Exhibit 99.2
Slide 2: Forward-looking statements
Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. T
Slide 3: Overview of the Merger Transaction
Share Exchange Agreement announced on 29th July 2020 Expected to be completed in Fall 2020 New company: F-star Therapeutics, Inc. expected to trade on NASDAQ under FSTX Dr. Eliot Forster to serve as President and CEO Combined company Board of Directors proportional to ownership spilt Pre-closing fin
Slide 4: The Promise of Immunotherapy
The Promise of Immunotherapy $23.5B >9.2M Immuno-oncology therapies sales in 2019** Immuno-oncology therapies approved to date 11 PD-1, PD-L1, CTLA-4 monoclonal antibodies - CAR-T - Immune stimulation led to transformational benefits >18.1M new cancer cases diagnosed in 2018* Cancer Deaths in 2018*
Slide 5: Large Unmet Medical Need
Large Unmet Medical Need F-star’s vision: Improving lives of Advancing differentiated novel immunotherapeutics Redirecting T cells to overcome cancer immune resistance of patients who currently fail to have a durable response to immunotherapy 80% patients have realized long-lasting benefits from app
Slide 6: Our Differentiated mAb2 Bispecific Technology Suggests Clinical Benefit
Differentiated MoA (3Cs): Crosslinking, Clustering and Conditionality Established manufacturing processes and promising safety profile 2 natural binding sites 2 new binding sites (no change in structure) Fc silencing Natural human antibody format Targeted bispecific with four binding sites for poten
Slide 7: 3Cs for Focused, Potent and Safe Immune Activation
Tumor cells Immune cell Clustering Crosslinking Conditionality Redirecting immune cells to a tumor Tumor cells Healthy cells 3Cs for Focused, Potent and Safe Immune Activation Reactivating exhausted immune cells Cancer directed activation Cancer Cell Killing Inducing New Biology Higher Therapeutic I
Slide 8: Pipeline of Next Generation Immunotherapeutics to Address Unmet Need
Pipeline of Next Generation Immunotherapeutics to Address Unmet Need 2020 mAb2 candidates 2021 Clinical Programs Targets Current Status Anticipated Next Steps Pre-clin IND Ph1 Ph2 FS118 LAG-3/PD-L1 Completion of Phase 1 trial expected in Q4:2020 Initiation of POC in acquired resistance head & neck c
Slide 9: FS118: LAG-3/PD-L1 mAb2 Bispecific Antibody
First-in-class with novel mechanism of action Potent PD-L1 and LAG-3 inhibition Phase 1 trial ongoing Initial data shows well tolerated with long term dosing Targeting disease control in checkpoint-resistant patient population Expect early 2021 initiation of POC in acquired resistance head & neck ca
Slide 10: FS118: Observed Disease Control of >60% in Checkpoint Acquired Resistance Patients
FS118: Observed Disease Control of >60 % in Checkpoint Acquired Resistance Patients Phase 1 in Checkpoint Acquired Resistance Population Median lines pre-treatment 6 Evaluable AR patients 26 ORR (unconfirmed) 4% (1/26) DCR 62% (16/26) PD-L1 LAG-3 Primary Acquired Patients receiving 1mg/kg and above
Slide 11: FS120: CD137/OX40 mAb2 Bispecific Antibody
First-in-class dual T cell agonist Triple Immune mechanism of action (CD4, CD8 and Treg) Monotherapy activity Synergy in combination with PD-1 Synergistic with broad range of chemotherapy Well tolerated in preclinical tox study at >10x anticipated clinical dose Open IND and IRB approval Expect to in
Slide 12: CD137/OX40 mAb2 Potently Augments the Activity of PD-1
In Preclinical Studies, CD137/OX40 mAb2 Potently Augments the Activity of PD-1 CD137 OX40 CT26 tumor model, PD-1 refractory (approx. 15 mice/group) Combination with PD-1 Increased anti-tumor response to PD-1 inhibition observed Correlation coefficient (co-expression) Biomarker lead development strat
Slide 13: FS222: CD137/PD-L1 mAb2 Bispecific Antibody
Redirecting activated immune cells to the tumor Potential for Best-in-class Potential for wider therapeutic window than mAb combinations or other bispecific approaches Potential for clinical differentiation in PD-L1 low setting Potential to move to earlier lines of treatment replacing current checkp
Slide 14: CD137/PD-L1 mAb2 Showed Superior Activity to Combination
In Preclinical Studies, CD137/PD-L1 mAb² Showed Superior Activity to Combination PD-L1 CD137 Survival of MC38 tumor-bearing mice Individual spider plots A highly potent molecule with strong preclinical in vivo activity 100% Tumor-free
Slide 15: SB 11285: Intravenously Administered Next Generation STING Agonist
SB 11285: An Intravenously Administered Next Generation STING Agonist Second generation intravenous STING agonist Preclinical studies indicate potential advantages over intratumoral STING agonists Phase 1/2 trial including combination with PD-L1 ongoing in US Currently patients are at the 3rd dose l
Slide 16: Experienced Management Team
Experienced Management Team Medical Oncologist with 25+ years' experience in clinical research in Europe and US Experience in registrational studies, registration strategy and drug approval Louis Kayitalire CMO, MD 25 years leading financial operations in public and private companies Proven track re
Slide 17: Board of Directors
Board of Directors Nessan Bermingham PhD, Chairman Co-Founder and previously CEO of Intellia Therapeutics, leading it through IPO (NASDAQ: NTLA). Founder and CEO of Triplet Therapeutics, Founder and Exec Chair of Korro Bio and venture partner at Atlas Venture. Previously Chair of Ex Nihlio, and inde
Slide 18: Anticipated Future Data Milestones
Anticipated Future Data Milestones SB 11285 Ph 1/2 update: preliminary safety from IV administered STING agonist FS222 initiation of PK/PD expansion cohorts: preliminary safety and Pharmacokinetics FS222 Update on dose escalation: exploring activity and informing biomarker strategy Q3 2020 Q4 2020 Q
Slide 19: Highlights of F-star Therapeutics
Highlights of F-star Therapeutics Multiple, anticipated near-term value adding clinical data milestones across four novel programs Proprietary, highly differentiated, bispecific antibody platform delivering multiple clinical programs Addressing fast growing market and burgeoning patients' needs in i
Slide 20: Thank you
at Estar” Thank you .
Spring Bank Pharmaceuticals — Merger or Acquisition (July 2020) on 6ix